[Sonnet BioTherapeutics Receives Shareholder Approval for Business Merger with Hyperliquid Strategies, Inc.] According to market reports, Nasdaq-listed biotechnology company Sonnet BioTherapeutics has received shareholder approval for a business merger with Hyperliquid Strategies, Inc. Previous reports indicated that the listed company Sonnet plans to rename itself Hyperliquid Strategies through the merger transaction, and is expected to hold 12.6 million HYPE tokens and $300 million in cash.